Question explored with the scientific record
Does folic acid supplementation increase cancer risk in randomized trials, and what do the pooled estimates show?
The short version: the pooled trial data do not show a clean cancer signal, but one large trial found a real increase in cancer deaths, and the pooled estimates are mixed enough that "no risk" is not established.
The most important single trial here is the JAMA 2009 study in heart disease patients. Folic acid plus B12 raised cancer incidence (hazard ratio 1.21), cancer mortality (1.38), and all-cause mortality (1.18) [1]. That is a hard clinical outcome, not a lab value, and it points the wrong way.
The pooled picture is messier. A meta-analysis of 10 randomized trials found no benefit but a borderline significant increase in overall cancer, with prostate cancer the only site showing increased risk [3]. That same review notes the trials often gave B12 and B6 alongside folic acid, so the signal cannot be pinned on folate alone [3]. A separate meta-analysis of 26 trials (58,804 people) found no increase in all-cause mortality (RR 1.0) [4]. For colorectal cancer, pooled observational data suggest lower risk (RR 0.85 to 0.88), while pooled trial data hover around null (RR 0.96 to 1.15) [2].
| Source | Outcome | Direction |
|---|---|---|
| JAMA 2009 trial [1] | Cancer incidence | Increased (HR 1.21) |
| JAMA 2009 trial [1] | Cancer mortality | Increased (HR 1.38) |
| 10-trial meta-analysis [3] | Overall cancer | Borderline increase |
| 26-trial meta-analysis [4] | All-cause mortality | Null (RR 1.0) |
| Colorectal meta-analyses [2] | Colorectal cancer | Observational lower, trial null |
The pattern fits a U-shaped risk curve: harm at very low and very high intake, least risk around 300 to 400 micrograms a day [3]. High-dose supplements sit in the upper arm. This retrieval does not include the large prostate cancer trial or the FDA-style long-term safety reviews, so the pooled estimate for cancer death specifically is not fully visible here.
My call: for a healthy person taking high-dose folic acid long term without a documented deficiency, the trial evidence does not clear it of a cancer-mortality signal, and the burden sits on the seller. Confidence: moderate.
Sources used 4
-
Cancer Incidence and Mortality After Treatment With Folic Acid and Vitamin B<sub>12</sub>
This study evaluates the effects of folic acid and vitamin B12 treatment on cancer incidence and mortality in patients with ischemic heart disease, revealing an association with increased cancer outcomes and all-cause mortality.
DOI: 10.1001/jama.2009.1622 -
Recent advances in clinical practice: colorectal cancer chemoprevention in the average-risk population
An umbrella review synthesizing 80 meta-analyses on colorectal cancer chemoprevention in average-risk adults, concluding that aspirin/NSAIDs show protective associations while meat and alcohol generally increase risk, but with predominantly low-quality evidence and substantial h…
DOI: 10.1136/gutjnl-2020-320990 -
Folic acid fortification prevents neural tube defects and may also reduce cancer risks
This review argues that mandatory folic acid fortification effectively prevents neural tube defects and that cancer-risk concerns are not supported at physiological intake levels, recommending EU implementation soon.
DOI: 10.1111/j.1651-2227.2012.02781.x -
Efficacy of folic acid supplementation in cardiovascular disease prevention: An updated meta-analysis of randomized controlled trials
This 2012 updated meta-analysis of 26 randomized controlled trials (58,804 participants) finds that folic acid supplementation does not significantly reduce cardiovascular disease or coronary heart disease risk or all-cause mortality, with a potential modest reduction in stroke …
DOI: 10.1016/j.ejim.2012.07.004